{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:22:34Z","timestamp":1776831754448,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T00:00:00Z","timestamp":1473984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25\u201330% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) has been proposed to be responsible for this process, but its relevance has been discussed controversially in recent times. Here we found that the multidrug and toxin extrusion protein 1 (MATE1) transports imatinib with a manifold higher affinity. MATE1 mainly mediates the cellular uptake of imatinib into targeted cells and thereby controls the intracellular effectiveness of imatinib. Importantly, MATE1 but not OCT1 expression is reduced in total bone marrow cells of imatinib-non-responding CML patients compared with imatinib-responding patients, indicating that MATE1 but not OCT1 determines the therapeutic success of imatinib. We thus propose that imatinib non-responders could be identified early before starting therapy by measuring MATE1 expression levels.<\/jats:p>","DOI":"10.1038\/bcj.2016.79","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T13:23:05Z","timestamp":1474032185000},"page":"e470-e470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients"],"prefix":"10.1038","volume":"6","author":[{"given":"S","family":"Harrach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Schmidt-Lauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Pap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Pavenst\u00e4dt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Schlatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W E","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Edemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ciarimboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"BFbcj201679_CR1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, M\u00fcller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFbcj201679_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823\u20131831.","journal-title":"Leukemia"},{"key":"BFbcj201679_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFbcj201679_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, NY) 2001; 293: 876\u2013880.","journal-title":"Science (New York, NY)"},{"key":"BFbcj201679_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/leu.2010.16","volume":"24","author":"JR Engler","year":"2010","unstructured":"Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL . Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010; 24: 765\u2013770.","journal-title":"Leukemia"},{"key":"BFbcj201679_CR6","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761\u20132767.","journal-title":"J Clin Oncol"},{"key":"BFbcj201679_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013; 121: 628\u2013637.","journal-title":"Blood"},{"key":"BFbcj201679_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","volume":"20","author":"AT Nies","year":"2013","unstructured":"Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M et al. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 2013; 20: 985\u2013994.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201679_CR9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1182\/blood-2013-11-535864","volume":"123","author":"MV Tzvetkov","year":"2014","unstructured":"Tzvetkov MV, Seitz T, Bokelmann K, Mueller T, Brockm\u00f6ller J, Koepsell H . Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity? Blood 2014; 123: 1427\u20131429.","journal-title":"Blood"},{"key":"BFbcj201679_CR10","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1182\/blood-2013-03-493841","volume":"121","author":"H Burger","year":"2013","unstructured":"Burger H, Mathijssen RHJ, Sparreboom A, Wiemer EAC . Can \u2018specific\u2019 OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib? Blood 2013; 121: 4965\u20134966.","journal-title":"Blood"},{"key":"BFbcj201679_CR11","doi-asserted-by":"publisher","first-page":"e52247","DOI":"10.1371\/journal.pone.0052247","volume":"7","author":"C Schmidt-Lauber","year":"2012","unstructured":"Schmidt-Lauber C, Harrach S, Pap T, Fischer M, Victor M, Heitzmann M et al. Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. PLoS One 2012; 7: e52247.","journal-title":"PLoS One"},{"key":"BFbcj201679_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","volume":"10","author":"T Minematsu","year":"2011","unstructured":"Minematsu T, Giacomini KM . Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011; 10: 531\u2013539.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201679_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1124\/jpet.107.131482","volume":"324","author":"G Minuesa","year":"2008","unstructured":"Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2008; 324: 558\u2013567.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFbcj201679_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","volume":"24","author":"H Koepsell","year":"2007","unstructured":"Koepsell H, Lips K, Volk C . Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227\u20131251.","journal-title":"Pharm Res"},{"key":"BFbcj201679_CR15","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"S Hu","year":"2008","unstructured":"Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141\u20133148.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201679_CR16","doi-asserted-by":"publisher","first-page":"F1504","DOI":"10.1152\/ajprenal.90754.2008","volume":"296","author":"W-K Lee","year":"2009","unstructured":"Lee W-K, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H et al. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 2009; 296: F1504\u2013F1513.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFbcj201679_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"International Transporter Consortium, Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, KLR Brouwer et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215\u2013236.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbcj201679_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P le Coutre","year":"2004","unstructured":"le Coutre P, Kreuzer K-A, Pursche S, Bonin MV, Leopold T, Baskaynak G et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004; 53: 313\u2013323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbcj201679_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar H-J . Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews 2009; 35: 692\u2013706.","journal-title":"Cancer Treatment Reviews"},{"key":"BFbcj201679_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/jpet.109.163642","volume":"333","author":"S Ito","year":"2010","unstructured":"Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010; 333: 341\u2013350.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFbcj201679_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.bjp.0704785","volume":"136","author":"M Hayer Zillgen","year":"2002","unstructured":"Hayer Zillgen M, Br\u00fcss M, B\u00f6nisch H . Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 2002; 136: 829\u2013836.","journal-title":"Br J Pharmacol"},{"key":"BFbcj201679_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1021\/jm301302s","volume":"56","author":"MB Wittwer","year":"2013","unstructured":"Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 2013; 56: 781\u2013795.","journal-title":"J Med Chem"},{"key":"BFbcj201679_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/00498250701397705","volume":"37","author":"K-I Umehara","year":"2007","unstructured":"Umehara K-I, Iwatsubo T, Noguchi K, Kamimura H . Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: insight into the development of drug candidates. Xenobiotica 2007; 37: 618\u2013634.","journal-title":"Xenobiotica"},{"key":"BFbcj201679_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFbcj201679_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ijc.2910180405","volume":"18","author":"E Klein","year":"1976","unstructured":"Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976; 18: 421\u2013431.","journal-title":"Int J Cancer"},{"key":"BFbcj201679_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuropharm.2006.01.005","volume":"50","author":"A Amphoux","year":"2006","unstructured":"Amphoux A, Vialou V, Drescher E, Br\u00fcss M, Mannoury la Cour C, Rochat C et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 2006; 50: 941\u2013952.","journal-title":"Neuropharmacology"},{"key":"BFbcj201679_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1124\/mol.104.004713","volume":"67","author":"WM Suhre","year":"2005","unstructured":"Suhre WM, Ekins S, Chang C, Swaan PW, Wright SH . Molecular determinants of substrate\/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol 2005; 67: 1067\u20131077.","journal-title":"Mol Pharmacol"},{"key":"BFbcj201679_CR28","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064\u20134072.","journal-title":"Blood"},{"key":"BFbcj201679_CR29","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFbcj201679_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann J-L, Shah NP, Boqu\u00e9 C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFbcj201679_CR31","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFbcj201679_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/tpj.2008.19","volume":"9","author":"Y Chen","year":"2009","unstructured":"Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009; 9: 127\u2013136.","journal-title":"Pharmacogenomics J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201679","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:51:16Z","timestamp":1672822276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,16]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9]]}},"alternative-id":["BFbcj201679"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.79","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,16]]},"assertion":[{"value":"4 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TH partly owns MLL Munich Leukemia Laboratory. SJ is employed by MLL Munich Leukemia Laboratory. The other authors declare no conflict of interest and nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}